Caterina Fanello

Caterina Fanello

Auto-generated profile, based on publicly available information

Caterina Fanello

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine Mahidol University Bangkok Thailand

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EAElizabeth A. Ashley
Elizabeth A. Ashley
MDMehul Dhorda
Mehul Dhorda
RFRick M. Fairhurst
Rick M. Fairhurst
CAChanaki Amaratunga
Chanaki Amaratunga
PLParath Lim
Parath Lim
NWNicholas J. White
Nicholas J. White
Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria. Mapping the geographic extent of resistance is essential for planning containment and elimination strategies. Between May 2011 and April 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa). Patients received artesunate, administered orally at a daily dose of either 2 mg per kilogram of body weight per day or 4 mg per kilogram, for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy. Parasite counts in peripheral-blood samples were measured every 6 hours, and the parasite clearance half-lives were determined. The median parasite clearance half-lives ranged from 1.9 hours in the Democratic Republic of Congo to 7.0 hours at the Thailand–Cambodia border. Slowly clearing infections (parasite clearance half-life >5 hours), strongly associated with single point mutations in the “propeller” region of the P. falciparum kelch protein gene on chromosome 13 (kelch13), were detected throughout mainland Southeast Asia from southern Vietnam to central Myanmar. The incidence of pretreatment and post-treatment gametocytemia was higher among patients with slow parasite clearance, suggesting greater potential for transmission. In western Cambodia, where artemisinin-based combination therapies are failing, the 6-day course of antimalarial therapy was associated with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.4) at 42 days. Artemisinin resistance to P. falciparum, which is now prevalent across mainland Southeast Asia, is associated with mutations in kelch13. Prolonged courses of artemisinin-based combination therapies are currently efficacious in areas where standard 3-day treatments are failing. (Funded by the U.K. Department of International Development and others; ClinicalTrials.gov number, NCT01350856.)

1 November 2010 in The Lancet
Verified
Journal Article
Open access
ADArjen M Dondorp
Arjen M Dondorp
CFCaterina I Fanello
Caterina I Fanello
IHIlse Ce Hendriksen
Ilse Ce Hendriksen
EGErmelinda Gomes
Ermelinda Gomes
ASAmir Seni
Amir Seni
NWNicholas J White
Nicholas J White
Severe malaria is a major cause of childhood death and often the main reason for paediatric hospital admission in sub-Saharan Africa. Quinine is still the established treatment of choice, although evidence from Asia suggests that artesunate is associated with a lower mortality. We compared parenteral treatment with either artesunate or quinine in African children with severe malaria. This open-label, randomised trial was undertaken in 11 centres in nine African countries. Children (<15 years) with severe falciparum malaria were randomly assigned to parenteral artesunate or parenteral quinine. Randomisation was in blocks of 20, with study numbers corresponding to treatment allocations kept inside opaque sealed paper envelopes. The trial was open label at each site, and none of the investigators or trialists, apart from for the trial statistician, had access to the summaries of treatment allocations. The primary outcome measure was in-hospital mortality, analysed by intention to treat. This trial is registered, number ISRCTN50258054. 5425 children were enrolled; 2712 were assigned to artesunate and 2713 to quinine. All patients were analysed for the primary outcome. 230 (8·5%) patients assigned to artesunate treatment died compared with 297 (10·9%) assigned to quinine treatment (odds ratio [OR] stratified for study site 0·75, 95% CI 0·63-0·90; relative reduction 22·5%, 95% CI 8·1-36·9; p=0·0022). Incidence of neurological sequelae did not differ significantly between groups, but the development of coma (65/1832 [3·5%] with artesunate vs 91/1768 [5·1%] with quinine; OR 0·69 95% CI 0·49-0·95; p=0·0231), convulsions (224/2712 [8·3%] vs 273/2713 [10·1%]; OR 0·80, 0·66-0·97; p=0·0199), and deterioration of the coma score (166/2712 [6·1%] vs 208/2713 [7·7%]; OR 0·78, 0·64-0·97; p=0·0245) were all significantly less frequent in artesunate recipients than in quinine recipients. Post-treatment hypoglycaemia was also less frequent in patients assigned to artesunate than in those assigned to quinine (48/2712 [1·8%] vs 75/2713 [2·8%]; OR 0·63, 0·43-0·91; p=0·0134). Artesunate was well tolerated, with no serious drug-related adverse effects. Artesunate substantially reduces mortality in African children with severe malaria. These data, together with a meta-analysis of all trials comparing artesunate and quinine, strongly suggest that parenteral artesunate should replace quinine as the treatment of choice for severe falciparum malaria worldwide. The Wellcome Trust.

19 January 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
OMOlivo Miotto
Olivo Miotto
RARoberto Amato
Roberto Amato
EAElizabeth A Ashley
Elizabeth A Ashley
BMBronwyn MacInnis
Bronwyn MacInnis
JAJacob Almagro-Garcia
Jacob Almagro-Garcia
DKDominic P Kwiatkowski
Dominic P Kwiatkowski

14 December 2002 in Medical and Veterinary Entomology
Verified
Journal Article
Closed access
PDF file
CFC. Fanello
C. Fanello
FSFederica Santolamazza
Federica Santolamazza
Alessandra della TorreAlessandra della Torre
Alessandra della Torre

1 February 2001 in Insect Molecular Biology
Verified
Journal Article
Closed access
PDF file
Alessandra della TorreAlessandra della Torre
Alessandra della Torre
CFC. Fanello
C. Fanello
MAM. Akogbeto
M. Akogbeto
JDJ. Dossou‐Yovo
J. Dossou‐Yovo
Guido FaviaGuido Favia
Guido Favia
MCM. Coluzzi
M. Coluzzi

12 March 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLorenz von Seidlein
Lorenz von Seidlein
RORasaq Olaosebikan
Rasaq Olaosebikan
IHIlse C. E. Hendriksen
Ilse C. E. Hendriksen
SLSue J. Lee
Sue J. Lee
OAOlanrewaju Timothy Adedoyin
Olanrewaju Timothy Adedoyin
ADArjen M. Dondorp
Arjen M. Dondorp
Background. Data from the largest randomized, controlled trial for the treatment of children hospitalized with severe malaria were used to identify such predictors of a poor outcome from severe malaria. Methods. African children (<15 years) with severe malaria participated in a randomized comparison of parenteral artesunate and parenteral quinine in 9 African countries. Detailed clinical assessment was performed on admission. Parasite densities were assessed in a reference laboratory. Predictors of death were examined using a multivariate logistic regression model. Results. Twenty indicators of disease severity were assessed, out of which 5 (base deficit, impaired consciousness, convulsions, elevated blood urea, and underlying chronic illness) were associated independently with death. Tachypnea, respiratory distress, deep breathing, shock, prostration, low pH, hyperparasitemia, severe anemia, and jaundice were statistically significant indicators of death in the univariate analysis but not in the multivariate model. Age, glucose levels, axillary temperature, parasite density, heart rate, blood pressure, and blackwater fever were not related to death in univariate models. Conclusions. Acidosis, cerebral involvement, renal impairment, and chronic illness are key independent predictors for a poor outcome in African children with severe malaria. Mortality is markedly increased in cerebral malaria combined with acidosis. Clinical Trial Registration. ISRCTN50258054.